View Post

PreludeDx Present Results from PREDICT Study at ASBrS Annual Meeting

In Clinical Trials by Barbara Jacoby

Source: Prelude Corporation From: prnewswire.com Prelude Corporation (PreludeDx), a leader in molecular diagnostics and personalized medicine for early stage breast cancer, presented interim results from its large PREDICT study during a poster presentation (Abstract ID: 581643), titled “Interim Analysis of the DCISionRT PREDICT Study: Clinical Utility of a Biologic Signature Predictive of Radiation Therapy (RT) Benefit in Patients with DCIS”, …

View Post

Denosumab Improves Bone Health, Disease-Free Survival in Hormone Receptor–Positive Breast Cancer

In In The News by Barbara Jacoby

By: Jaime Rosenberg From: ajmc.com In postmenopausal women with hormone receptor–positive, early-stage breast cancer receiving treatment with aromatase inhibitor therapy, the addition of denosumab results in a significant reduction in clinical fractures, according to results of a new study, which also found that the treatment yielded benefits for disease-free survival. While aromatase inhibitor therapy is the standard of care for …

View Post

Genomic Assays Advance Personalized Care in Early-Stage Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Caroline Seymour eFrom: onclive.com The collective results of the MINDACT and TAILORx trials provided a better directive in terms of whether or not to give endocrine therapy alone or in combination with chemotherapy for patients with node-negative, early-stage hormone receptor (HR)–positive, HER2-negative breast cancer, said Mariana Chavez Mac Gregor, MD, MSc. “In patients who have early-stage HR-positive, HER2-negative disease, …

View Post

Biotheranostics’ Breast Cancer Index® Recently Recognized in Two National Clinical Practice Guidelines

In In The News by Barbara Jacoby

From: businesswire.com Clinical Practice Guidelines Recognize Breast Cancer Index Clinical Utility Spans the Treatment Continuum for Patients with Early-Stage Estrogen Receptor Positive (ER+) Disease Breast Cancer Index Endorsed in National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer and American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Focused Update Biotheranostics, Inc. announces recommendations for Breast Cancer Index …